Ensuring the involvement of children in the evaluation of new tuberculosis treatment regimens

PLoS Medicine

Volumn 5, Issue 8, 2008, Pages 1168-1172

  Burman, William J ^a   Cotton, Mark F ^b   Gibb, Diana M ^c   Walker, A Sarah ^c   Vernon, Andrew A ^d   Donald, Peter R ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF STELLENBOSCH   (South Africa)

^c MEDICAL RESEARCH COUNCIL   (United Kingdom)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

CLINICAL EVALUATION; CLINICAL TRIAL; DRUG TOLERABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; LIVER TOXICITY; LUNG TUBERCULOSIS; NAUSEA; REVIEW; THORAX RADIOGRAPHY; TREATMENT DURATION; VOMITING; ARTICLE; CHILD; CLINICAL TRIAL (TOPIC); DRUG DESIGN; EVALUATION; INFANT; RADIOGRAPHY;

CHILD; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; EVALUATION STUDIES AS TOPIC; HUMANS; INFANT; RADIOGRAPHY, THORACIC; TUBERCULOSIS, PULMONARY;

EID: 51149095205     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0050176     Document Type: Review

References (42)

1. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, et al. (2006) Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368: 1575-1580.
2. Rosenthal IM, Zhang M, Williams KN, Peloquin CA, Tyagi S, et al. (2007) Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med 4: e344. doi:10.1371/joumal.pmed.0040344
3. Chapuis L, Ji B, Truffot-Pernot C, O'Brien RJ, Raviglione MC, et al. (1994) Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice. Am J Respir Crit Care Med 150: 1355-1362.
4. Matsumoto M, Hashizume H, Tomishige T, Kawasaki M, Tsubouchi H, et al. (2006) OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 3: e466. doi:10.1371/journal.pmed.0030466
5. Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM, et al. (2000) A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405: 962-966.
6. Nikonenko BV, Protopopova M, Samala R, Einck L, Nacy CA (2007) Drug therapy of experimental tuberculosis (TB): Improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs. Antimicrob Agents Chemother 51: 1563-1565.
7. Lounis N, Veziris N, Chauffour A, Truffot-Pernot C, Andries K, et al. (2006) Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration. Antimicrob Agents Chemother 50: 3543-3547.
8. Ragno R, Marshall GR, Di Santo R, Costi R, Massa S, et al. (2000) Antimycobacterial pyrroles: synthesis, anti-Mycobacterium tuberculosis activity and QSAR studies. Bioorg Med Chem 8: 1423-1432.
9. Nelson LJ, Wells CD (2004) Global epidemiology of childhood tuberculosis. Int J Tuberc Lung Dis 8: 636-647.
10. Marais BJ, Graham SM, Cotton MF, Beyers N (2007) Diagnostic and management challenges for childhood tuberculosis in the era of HIV. J Infect Dis 196 (Suppl 1): S76-S85.
11. Marais BJ, Gie RP, Schaaf HS, HesselingAC, Enarson DA, et al. (2006) The spectrum of disease in children treated for tuberculosis in a highly endemic area. Int J Tuberc Lung Dis 10: 732-738.
12. Marais BJ, Gie RP, Schaaf HS, Hesseling AC, Obihara CC, et al. (2004) The natural history of childhood intra-thoracic tuberculosis: A critical review of literature from the prechemotherapy era. Int J Tuberc Lung Dis 8: 392-402.
13. Tuberculosis Trials Consortium (2008) TBTC Study 26: Weekly RFP/INH for 3 mo. vs. daily INH for 9 mo. for the treatment of LTBI. Available: http://www.clinicaltrials.gov/ct2/ show/NCT00023452?term=tuberculosis%2C+ri fapentine&rank=5. Accessed 17July 2008.
14. Medical Research Council (1948) Streptomycin treatment of pulmonary tuberculosis. BMJ 1: 769-782.
15. Fox W, Ellard GA, Mitchison DA (1999) Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946-1986, with relevant subsequent publications. IntJ Tuberc Lung Dis 3: S231-S279.
16. Schaaf HS, Parkin DP, Seifart HI, Werely CJ, Hesseling PB, et al. (2005) Isoniazid pharmacokinetics in children treated for respiratory tuberculosis. Arch Dis Child 90: 614-618.
17. Donald PR (2007) The assessment of new antituberculosis drugs for a paediatric indication. Int J Tuberc Lung Dis 11: 1162-1165.
18. Gibb DM, Duong T, Tookey PA, Sharland M, Tudor-Williams G, et al. (2003) Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland. BMJ 327: 1019.
19. Bolton-Moore C, Mubiana-Mbewe M, Cantrell RA, Chintu N, Sninger EM, et al. (2007) Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia. JAMA 298: 1888-1899.
20. Gortmaker SL, Hughes M, Cervia J, Brady M, Johnson GM, et al. (2001) Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HTV-1. N Engl J Med 345: 1522-1528.
21. Palella F Jr, Delaney K, Moorman A, Loveless M, Fuhrer J, et al. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 338: 853-860.
22. Havens PL, Gibb DM (2007) Increasing antiretroviral drug access for children with HIV infection. Pediatrics 119: 838-845.
23. Zar HJ, Tannenbaum E, Apolles P, Roux P, Hanslo D, et al. (2000) Sputum induction for the diagnosis of pulmonary tuberculosis in infants and young children in an urban setting in South Africa. Arch Dis Child 82: 305-308.
24. Marais BJ, Hesseling AC, Gie RP, Schaaf HS, Enarson DA, et al. (2006) The bacteriologic yield in children with intrathoracic tuberculosis. Clin Infect Dis 42: e69-e71.
25. Chow F, Espiritu N, Gilman RH, Gutierrez R, Lopez S, et al. (2006) La cuerda dulce-A tolerability and acceptability study of a novel approach to specimen collection for diagnosis of paediatric pulmonary tuberculosis. BMC Infect Dis 6: 67.
26. Vargas D, Garcia L, Gilman RH, Evans C, Ticona E, et al. (2005) Diagnosis of sputumscarce HIV-associated pulmonary tuberculosis in Lima, Peru. Lancet 365: 150-152.
27. Marais BJ, Gie RP, Hesseling AC, Schaaf HS, Lombard C, et al. (2006) A refined symptom-based approach to diagnose pulmonary tuberculosis in children. Pediatrics 118: e1350-e1359.
28. Zar HJ, Cotton MF, Sn-auss S, Karpakis J, Hussey G, et al. (2007) Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: Randomised controlled trial. BMJ 334: 136.
29. Lindtjorn B, Madebo T (2001) The outcome of tuberculosis treatment at a rural hospital in southern Ethiopia. Trop Doct 31: 132-135.
30. Tanguis HG, Cayla JA, Garcia de Olalla PG, JansaJM, Brugal MT (2000) Factors predicting non-completion of tuberculosis treatment among HIV-infected patients in Barcelona (1987-1996). Int J Tuberc Lung Dis 4: 55-60.
31. Radilla-Chavez P, Laniado-Laborin R (2007) Results of directly observed treatment for tuberculosis in Ensenada, Mexico: Not all DOTS programs are created equally. Int J Tuberc Lung Dis 11: 289-292.
32. Hesseling AC, Schaaf SH, Westra AE, Werschkull H, Donald PR, et al. (2005) Outcome of HIV-infected children with culture-confirmed tuberculosis. Arch Dis Child.
33. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, etal. (2003) Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 167: 1472-1477.
34. Meibohm B, Laer S, PanettaJC, Barrett JS (2005) Population pharmacokinetic studies in pediatrics: Issues in design and analysis. AAPS J 7: E475-E487.
35. Barnes KI, Lindegardh N, Ogundahunsi O, Olliaro P, Plowe CV, et al. (2007) World Antimalarial Resistance Network (WARN) IV: Clinical pharmacology. Malar J 6: 122.
36. United States Congress (2007) Food and Drug Administration Amendments Act of 2007. HR 3580. 110th Cong. Available: http://www.fda. gov/oc/initiatives/ HR3580.pdf. Accessed 17 July 2008.
37. European Medicines Agency (2007) The EU Paediatric Regulation. Available: http://www. emea.europa.eu/htms/human/paediatrics/ regulation.htm. Accessed 17 July 2008.
38. World Health Organization (2006) Intergovernmental Working Group on Public health, Innovation and Intellectual Property. Available: http://www.who.int/mediacentre/ events/2006/intellectual.property.meeting/ en/index.html. Accessed 17 July 2008.
39. Feuer C (2007) Tuberculosis research and development: A critical analysis of funding trends, 2005-2006. Treatment Action Group. Available: http://www.aidsinfonyc.org/tag/ tbhiv/tbrandd/2007tbranddreport.pdf. Accessed 17 July 2008.
40. Mitnick C, Bayona J, Palacios E, Shin S, Furin J, et al. (2003) Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 348: 119-128.
41. Badri M, Maartens G, Mandalia S, Bekker LG, Pernod JR, et al. (2006) Cost-effectiveness of highly active antiretroviral therapy in South Africa. PLoS Med 3: e4. doi:10.1371/journal. pmed.0030004
42. Fairall LR, Bachmann MO, Louwagie GM, van Vuuren C, Chikobvu P, et al. (2008) Effectiveness of antiretroviral treatment in a South African program: A cohort study. Arch Intern Med 168: 86-93.